Milestone Alert: Last Patient Completes Phase 3 Study of Biofrontera’s Ameluz PDT for AKs on the Extremities, Neck, and Trunk
The final patient completed the active treatment phase of Biofrontera Inc.’s Phase 3 trial evaluating Ameluz (10% 5-aminolevulinic acid hydrochloride gel) photodynamic therapy (PDT) for mild-to-moderate actinic keratoses (AKs) on the extremities, neck, and trunk.